Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Durable remission of thrombotic thrombocytopenic purpura in the setting of pembrolizumab therapy.
Journal: Transfusion
Published: November 03, 2022
Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder.
Journal: Pancreas
Published: February 13, 2020
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Journal: British journal of haematology
Published: May 17, 2017
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: September 29, 2016
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Journal: Annals of hematology
Published: April 05, 2016
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
Journal: Annals of hematology
Published: April 05, 2016
A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: May 27, 2014
Evaluation of long-term cardiovascular effects.
Journal: Reviews in cardiovascular medicine
Published: April 26, 2014
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Journal: British journal of haematology
Published: June 20, 2012
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Journal: Leukemia
Published: February 23, 2012
Last Updated: 09/26/2026